Revised forecast
Fiscal year ending December 2026 · Full yearPrevious forecast published 12 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The initially expected milestone income of approximately ¥40 million will no longer be generated due to a change in the collaborative drug discovery research plan caused by circumstances on the partner company's side. New contracts are also not expected to be executed until the fiscal year ending December 2027 at the earliest. While research and development expenses are expected to decrease by approximately ¥122 million, selling, general and administrative expenses other than research and development expenses are expected to increase by approximately ¥26 million, and an extraordinary loss of ¥187 million is expected to arise from impairment charges.
Extraordinary loss of ¥187 million from impairment charges on buildings and attached structures, and tools, furniture and fixtures placed into use in fiscal 2026
| Item | Details |
|---|---|
| Net Sales | ¥113 million → ¥70 million（-38.6%） |
| Operating profit | ¥-569 million → ¥-515 million |
| Ordinary income | ¥-564 million → ¥-509 million |
| Profit attributable to owners of the parent | ¥-567 million → ¥-700 million |
| Net income per share | -87.44 Yen / sen → -107.95 Yen / sen |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 12 February 2026 |
| Previous-period results | Fiscal year ended December 2025: business revenue ¥91 million, operating loss ¥396 million, ordinary loss ¥390 million, net loss for the period ¥425 million, net loss per share ¥65.62 |
| Reason for the revision | The initially expected milestone income of approximately ¥40 million will no longer be generated due to a change in the collaborative drug discovery research plan caused by circumstances on the partner company's side. New contracts are also not expected to be executed until the fiscal year ending December 2027 at the earliest. While research and development expenses are expected to decrease by approximately ¥122 million, selling, general and administrative expenses other than research and development expenses are expected to increase by approximately ¥26 million, and an extraordinary loss of ¥187 million is expected to arise from impairment charges. |
| Details and amount of extraordinary loss | Extraordinary loss of ¥187 million from impairment charges on buildings and attached structures, and tools, furniture and fixtures placed into use in fiscal 2026 |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The research plan for the collaborative drug discovery research was changed due to circumstances on the partner company's side, and the initially expected milestone income of approximately ¥40 million will no longer be generated. In addition, new contracts are not expected to be executed until the fiscal year ending December 2027 at the earliest. Although operating profit is expected to improve due to lower research and development expenses and other factors, net profit for the period will deteriorate because an extraordinary loss of ¥187 million will be recognized as a result of impairment charges on buildings and attached structures, and tools, furniture and fixtures.